News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medicsight (MSHT.OB) Launches ColonCAD(TM) Online CTC Platform


6/29/2009 11:15:37 AM

NEW YORK, June 29 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software that assists radiologists in the early detection of disease, is pleased to announce the launch of its online product, MedicRead(TM) 3.0 Colon. This online offering makes the benefits of Medicsight's ColonCAD software truly accessible to all radiologists for the first time.

MedicRead(TM) 3.0 Colon is Medicsight's advanced visualization platform that includes the Company's ColonCAD(TM) software. MedicRead(TM) 3.0 Colon allows radiologists to read computer tomography (CT) scans for the detection of colonic polyps, which may be the precursors of colon cancer. MedicRead(TM) 3.0 Colon can be downloaded from the Internet at www.medicsight.com and will be sold as a total solution with either a single list price or available on a monthly installment basis over 12 months.

Allan Rowley, Chief Executive of Medicsight, commented, "The launch of the online MedicRead 3.0 Colon platform provides us with an additional distribution channel for our exciting ColonCAD(TM) software. The MedicRead 3.0 Colon platform is currently the only visualization workstation for virtual colonoscopy that can be accessed and downloaded via the Internet. This broad access allows us to reach a broader user base and allows the international radiology community the ability to take advantage of the clinical benefits of our ColonCAD."

Access to Medicsight's ColonCAD(TM) software is currently available through its partners' advanced 3D visualization platforms. As part of Medicsight's ongoing commitment to radiologists and to improving the early detection of colorectal cancer, Medicsight has developed MedicRead 3.0 Colon. This is a competitively priced, standalone, CTC visualization workstation that incorporates the latest version of ColonCAD 4.0 as well as Medicsight's MedicServer(TM) technology. MedicRead 3.0 Colon offers a valuable centralized pre-processing platform that accepts DICOM CT image data from either the CT console or any PACS system.

A 30-day free trial version of the software can be downloaded from the Medicsight new website www.medicsight.com, allowing radiologists to experience the benefits of ColonCAD first-hand.

The new online application was showcased at the Medicsight booth at ESGAR 2009, which took place last week in Valencia, Spain.

Medicsight's ColonCAD technology has been approved for use in the European Union, China, Canada and Brazil. MedicRead 3.0 Colon is not currently available for sale in the United States.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange Ltd.

Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualization workstations of several industry-leading imaging equipment partners.

Medicexchange Ltd. provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

CONTACT: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or Garth Russell,
+1-212-896-1250, grussell@kcsa.com, both of KCSA Strategic Communications

Web site: http://www.mgtci.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES